Cryptococcus neoformans and Cryptococcus gattii are World Health Organization critical and medium priority pathogens, respectively. These mainly impac…

People in at least eight states have been infected with Chagas, new report says, amid low awareness of disease

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new drugs to treat fungal infections

Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi), is responsible for a large health burden with around 6–8 million people infected globally. The current dru...

YouTube video by Drugs for Neglected Diseases initiative (DNDi)

Over 200 guests gathered at the Swiss Tropical and Public Health Institute (Swiss TPH) in Allschwil today to celebrate the launch of Marcel Tanner’s biography. The festive event...

An Open Letter to Keir Starmer We, the undersigned, strongly advise against the proposed changes to the UK immigration system of May 12, 2025, and your associated rhetoric. We are UK-based academics.....

The Gateway to Research: UKRI portal onto publically funded research

An academic position as a Research Fellow (110168-0225) is being advertised on jobs.ac.uk. Click now to find more details and explore additional academic job opportunities.

Bölët Mouna means ‘sleeping sickness no more’ in Guinea’s national language Susu and tells the story of how research, innovation, and science are ending the the nightmare of sleeping sickness in Guinea. In January 2025 Guinea announced that it had eliminated sleeping sickness as a public health problem. This is the first disease that the country can claim to have eliminated and a major milestone in the Africa-wide campaign to eliminate sleeping sickness. The National Sleeping Sickness Programme in Guinea and its international partners – among them the French National Research Institute for Sustainable Development (IRD), the Drugs for Neglected Diseases initiative (DNDi), and the Institute Pasteur – have used all the tools at their disposal to achieve this milestone: small ‘tiny traps’ that dot the mangrove coasts of Guinea, rapid diagnostic tests, and revolutionary new medicines that are changing how doctors treat their patients. Read more about this achievement: https://stories.dndi.org/boletmouna/ Regarder en français: https://youtu.be/0S-ZSNcQEvY The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit developing safe, effective, and affordable treatments for the most neglected patients. https://dndi.org

At DNDi, our work begins with our people: we aim to recruit people who both reflect and understand the diversity of needs and experiences of those we serve.

Trypanosoma cruzi, the causative agent of Chagas disease, exhibits a complex life cycle with multiple hosts, stages and differentiation steps. We present a complete cell atlas for the T. cruzi life cy...

The proteasome is considered an excellent drug target for many infectious diseases as well as cancer. Challenges with robust and safe supply of proteasomes from infectious agents, lack of structural information, and complex pharmacology due to multiple active sites have hampered progress in the infectious disease space. We recombinantly expressed the proteasome of the protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease, and demonstrate pharmacological equivalence to the native T. cruzi proteasome.

PhD Project - EastBio: Keeping up with the Joneses: how do trypanosome parasites adapt to coinfection with other trypanosomes? at University of Edinburgh, listed on FindAPhD.com

The DDU tackles unmet medical needs through small molecule drug discovery, bridging the gap between academic scientific research and commercial drug development